Amgen Inc. (AMGN) To Go Ex-Dividend on November 21st

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, October 31st. Stockholders of record on Friday, November 21st will be paid a dividend of 2.38 per share by the medical research company on Friday, December 12th. This represents a c) dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st.

Amgen has increased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 14 years. Amgen has a payout ratio of 44.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $9.52 annual dividend with an expected future payout ratio of 44.5%.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $344.25 on Wednesday. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The firm has a market capitalization of $185.37 billion, a PE ratio of 28.07, a P/E/G ratio of 2.61 and a beta of 0.45. Amgen has a 1-year low of $253.30 and a 1-year high of $345.84. The business’s fifty day moving average price is $297.43 and its two-hundred day moving average price is $291.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the firm earned $5.58 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen will post 20.62 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on AMGN. HSBC raised their price target on shares of Amgen from $343.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings raised Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Bank of America lifted their target price on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Cantor Fitzgerald boosted their price target on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, DZ Bank increased their price target on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average price target of $319.90.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.